CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Toshifumi Hibi, Isao Kamae, Philippe Pinton, Lyann Ursos, Ryuichi Iwakiri, Greg Hather, Haridarshan Patel
Intest Res. 2021;19(1):53-61.   Published online April 22, 2020
DOI: https://doi.org/10.5217/ir.2019.09146

Excel Download

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Intestinal Research. 2021;19(1):53-61   Crossref logo
Link1 Link2 Link3

P038 NETWORK META-ANALYSIS: COMPARATIVE EFFICACY OF BIOLOGICS IN THE TREATMENT OF BIOLOGIC-NAïVE JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Gastroenterology. 2019;156(3):S27-S28   Crossref logo
Link1 Link2

P038 NETWORK META-ANALYSIS: COMPARATIVE EFFICACY OF BIOLOGICS IN THE TREATMENT OF BIOLOGIC-NAïVE JAPANESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Inflammatory Bowel Diseases. 2019;25(Supplement_1):S19-S19   Crossref logo
Link1

PGI3 A Network Meta-Analysis to Compare Efficacy of Filgotinib with Other Treatments in Biologic-Naïve Patients with Moderately to Severely Active Ulcerative Colitis
Value in Health. 2021;24:S95   Crossref logo
Link1 Link2

PGI2 A Network Meta-Analysis to Compare Efficacy of Filgotinib with Other Treatments in Biologic-Experienced Patients with Moderately to Severely Active Ulcerative Colitis
Value in Health. 2021;24:S95   Crossref logo
Link1 Link2

PGI9 Cost-Effectiveness Comparison of Vedolizumab, Infliximab and Conventional Therapy for the Treatment of Biologic-Naïve, Moderately to Severely ACTIVE Ulcerative Colitis Patients in China
Value in Health. 2020;23:S534   Crossref logo
Link1 Link2

DOSE ESCALATION OF BIOLOGIC THERAPIES IN BIOLOGIC TREATMENT-NAÏVE ADULT PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE ODESSA DATABASE STUDY
Gastroenterology. 2022;162(3):S9-S10   Crossref logo
Link1 Link2

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i037-i041   Crossref logo
Link1 Link2

PGI5 Cost per Responder Analysis of Biologic Treatments for Ulcerative Colitis in Biologic Naïve Patients from the Brazilian Private Healthcare System Perspective
Value in Health. 2020;23:S533   Crossref logo
Link1 Link2

P471 Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i443-i444   Crossref logo
Link1 Link2